Request Info


Ask for our annual reports or more information
Email Us

Email Alerts

Sign up for email alerts
Email Alerts
Investor Relations

News Releases

RSS RSS Feeds
News Release Search
2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998
DateTitle  
12/20/2004Meridian Bioscience Announces Second Partial Redemption of Its 7% Convertible Subordinated Debentures
CINCINNATI, Dec 20, 2004 (BUSINESS WIRE) -- Meridian Bioscience, Inc., (NASDAQ:VIVO) today announced that it has called for redemption on January 14, 2005, four million dollars ($4 million) in principal amount of its outstanding 7% Convertible Subordinated Debentures due September 1, 2006, at par plus accrued interest. The called 7% Convertible Debentures will be selected in accordance with the applicable procedures of the Trustee, U.S. Bank, National Association, for partial redemption. ... 
 Printer Friendly Version
11/17/2004Meridian Bioscience Reports Record Fiscal 2004 Operating Results and Increases Regular Cash Dividend Rate for Fiscal 2005
CINCINNATI--(BUSINESS WIRE)--Nov. 17, 2004--Meridian Bioscience, Inc., (NASDAQ:VIVO) GENERAL HIGHLIGHTS Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today: reported record fiscal 2004 net sales of $79.6 million and diluted earnings per share of $0.60, respective increases of 21% and 28% over the prior fiscal year; reported record fourth quarter fiscal 2004 net sales of $22.2 million and diluted earnings per share of $0.19... 
 Printer Friendly Version
11/15/2004Meridian Bioscience Increases Fiscal 2005 Earnings Per Share Guidance
CINCINNATI, Nov 15, 2004 (BUSINESS WIRE) -- Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today increased its previous guidance for fiscal 2005 earnings from a range of $0.62 to $0.66 per share to a new range of $0.66 to $0.70 per share. The per share estimates assume an increase in average shares outstanding from approximately 15.3 million at fiscal 2004 year end to 15.6 million at fiscal 2005 year end. Management continues to believe net sales will be in the range of $84 to ... 
 Printer Friendly Version
11/10/2004Meridian Signs Agreement in Principle to Acquire Leading Manufacturer and Distributor of Biological Components
CINCINNATI--(BUSINESS WIRE)--Nov. 10, 2004--Meridian Bioscience, Inc., (Nasdaq:VIVO) today announced it has executed a letter of intent to acquire all the outstanding capital stock of O.E.M. Concepts, Inc., a leading producer and distributor of biological components headquartered in Toms River, New Jersey. The purchase price includes cash and future performance-based earn out opportunities, the amounts of which were not disclosed. O.E.M. Concepts' management team will remain in place and ... 
 Printer Friendly Version
10/21/2004Meridian Bioscience Again Recognized by Forbes as One of the 200 Best Small Companies
CINCINNATI--(BUSINESS WIRE)--Oct. 21, 2004--Meridian Bioscience, Inc., (Nasdaq:VIVO) today announced that it has been recognized by Forbes as one of "The 200 Best Small Companies" for the second year in a row. The 200 Best Small Companies list is selected following a comprehensive evaluation of financial results plus additional operating factors of candidate companies having sales between $5 million and $750 million. Additional qualification criteria included a consistent pattern of posit... 
 Printer Friendly Version
10/5/2004Meridian Bioscience Announces Award Of SBIR Grant and Submission of Proposal for Biodefense Program
CINCINNATI--(BUSINESS WIRE)--Oct. 5, 2004--Meridian Bioscience, Inc. (Nasdaq:VIVO) announced today it has been awarded a Phase I Small Business Innovation Research (SBIR) Grant from the National Institutes of Health (NIH). This Phase I Grant will help fund research to develop highly specific recombinant antibodies to Clostridium difficile toxins A&B and then use these unique antibodies to develop rapid, inexpensive and sensitive diagnostics. Meridian will continue to pursue additional ... 
 Printer Friendly Version
9/23/2004Meridian Bioscience to Present at UBS Global Life Science Conference
CINCINNATI--(BUSINESS WIRE)--Sept. 23, 2004--Meridian Bioscience, Inc. (Nasdaq:VIVO) today announced that the Company has been invited to present at the UBS Global Life Science Conference, Wednesday, September 29, 2004 at 4:30 p.m. EDT at the Grand Hyatt New York in New York City. Jack Kraeutler, President and Chief Operating Officer, has been scheduled to present. A question and answer session will follow and some of the information provided during the session may not have been previousl... 
 Printer Friendly Version
8/26/2004Meridian Bioscience Announces FDA Clearance of New Rapid Test for Severe Colitis
CINCINNATI--(BUSINESS WIRE)--Aug. 26, 2004--Meridian Bioscience, Inc., Cincinnati, Ohio (Nasdaq:VIVO) today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) to market ImmunoCard Toxins A&B, a rapid new test for the diagnosis of a major cause of antibiotic-associated colitis. This test detects the most important toxins produced by strains of the Clostridium difficile bacterium (C. difficile). C. difficile is recognized as the major cause of colitis ... 
 Printer Friendly Version
8/3/2004Meridian Bioscience Provides Sales and Earnings Guidance for Fiscal 2005
CINCINNATI--(BUSINESS WIRE)--Aug. 3, 2004--Meridian Bioscience, Inc., (Nasdaq:VIVO) today provided the financial community with guidance regarding the Company's fiscal 2005 sales and earnings estimates. Based on the Company's business planning and budgeting activities, for the fiscal year ending September 30, 2005, management expects net sales to be in the range of $84 to $88 million and per share diluted earnings to be between $0.62 and $0.66. The per share estimates assume an increase i... 
 Printer Friendly Version
8/2/2004Meridian Bioscience to Present at Baird's 2004 Small Cap Conference
CINCINNATI--(BUSINESS WIRE)--Aug. 2, 2004--Meridian Bioscience, Inc. (Nasdaq:VIVO) today announced that Bill Motto, Chairman and Chief Executive Officer; Jack Kraeutler, President and Chief Operating Officer; and Rick Eberly, Executive Vice President and General Manager, Meridian Life Science, have been invited to present at Baird's 2004 Small Cap Conference Wednesday, August 4, 2004 at 2:20 p.m. EDT at the Pierre Hotel in New York City. A question and answer session will follow and some ... 
 Printer Friendly Version
7/22/2004Meridian Bioscience Reports Record Third Quarter Sales, Higher Earnings, Declares Regular Dividend, and Reaffirms Fiscal 2004 Guidance
CINCINNATI--(BUSINESS WIRE)--July 22, 2004--Meridian Bioscience, Inc., (Nasdaq:VIVO) today: reported record third quarter sales of $18,256,000, a 16% increase over last year's third quarter; reported diluted earnings per share of $0.14, a 17% increase over the same period last year; declared a regular cash dividend of $0.10 per share, 11% higher than the quarterly rate of fiscal 2003; and reaffirmed its recently increased guidance of sales be... 
 Printer Friendly Version
6/29/2004Meridian Bioscience Recognized as One of Ohio's Top Exporters in 2004
CINCINNATI--(BUSINESS WIRE)--June 29, 2004--Meridian Bioscience, Inc., (Nasdaq:VIVO) today announced that it has been recognized by the Governor of the State of Ohio, the Honorable Bob Taft, as one of Ohio's top exporters in 2004. Meridian was honored with a Governor's Excellence in Exporting Award ("E" Award) in a ceremony on June 24, 2004. The Governor's "E" Award recognizes Ohio companies that have increased sales through exports, have increased Ohio-Based employment as a direct ... 
 Printer Friendly Version
6/3/2004Meridian Bioscience Enters Strategic Collaboration With Viral Therapeutics
CINCINNATI--(BUSINESS WIRE)--June 3, 2004--Meridian Bioscience, Inc., Cincinnati, Ohio (Nasdaq:VIVO) today announced that its wholly-owned subsidiary, Viral Antigens, Inc. (VAI), has entered into a strategic collaboration with Viral Therapeutics, Inc. (VTI), Ithaca, NY, to support the clinical and commercial development needs of biopharmaceutical partners. Viral Therapeutics is an expert in the development of recombinant proteins and in production optimization. Viral Antigens' expertise i... 
 Printer Friendly Version
5/26/2004Meridian Bioscience Announces Licensing Agreement With Cincinnati Children's Research Foundation
CINCINNATI--(BUSINESS WIRE)--May 26, 2004--Meridian Bioscience, Inc. (Nasdaq:VIVO) today announced that it has entered into a license agreement with Cincinnati Children's Research Foundation for technologies related to the detection of norovirus, the primary cause of "stomach flu". This agreement, which is comprised of both exclusive and co-exclusive provisions, encompasses products for the clinical diagnosis of noroviruses and other products arising from the technology. Noroviruse... 
 Printer Friendly Version
5/17/2004Meridian Bioscience Announces European Launch of New Rapid Test for Severe Colitis
CINCINNATI--(BUSINESS WIRE)--May 17, 2004--Meridian Bioscience, Inc., (Nasdaq:VIVO) today announced that it has begun to sell its newest product, ImmunoCard Toxins A&B in the European market. This important new test detects toxins produced by strains of the Clostridium difficile bacterium (C. difficile). C. difficile is recognized as the major causative agent of colitis (inflammation of the colon) and diarrhea that may occur following antibiotic therapy. In hospitals or nursing home facil... 
 Printer Friendly Version
4/22/2004Meridian Bioscience Reports Record Sales, Higher Per Share Earnings, Declares Regular Cash Dividend, and Increases Fiscal 2004 Guidance
CINCINNATI--(BUSINESS WIRE)--April 22, 2004--Meridian Bioscience, Inc., Cincinnati, Ohio (Nasdaq:VIVO) today: reported all-time record quarterly sales of $20,940,000, a 24% increase over the same period of the prior fiscal year and all-time record for any quarter in the Company's history; reported all-time record quarter operating income of $3,981,000, an increase of 5% over the same period of the prior fiscal year and an all-time record for ... 
 Printer Friendly Version
3/18/2004Meridian Bioscience Added to Mergent's Dividend Achievers Index
CINCINNATI--(BUSINESS WIRE)--March 18, 2004--Meridian Bioscience, Inc. (Nasdaq:VIVO) today announced that it has been added to Mergent's Dividend Achievers Index(TM) for 2004. This index is made up of 303 stocks composed of U.S. companies with the most consistent records of annual dividend increases. Quoting from Mergent's press release "Dividend Achievers(TM) are publicly listed U.S. companies that have increased regular dividends for the past 10 consecutive years or longer, and th... 
 Printer Friendly Version
2/3/2004Meridian Bioscience Granted International ISO Certification to Manufacture Medical Devices for Export
CINCINNATI--(BUSINESS WIRE)--Feb. 3, 2004--Meridian Bioscience, Inc., (Nasdaq:VIVO) today announced that it has completed all activities required for ISO 13485 registration and final certification. ISO 13485 is a quality systems approach to managing the processes for manufacturing medical devices to ensure that they conform to customer expectations and governmental standards. More than 75 countries recognize ISO 13485 as the standard of practice for medical device manufacturing. In... 
 Printer Friendly Version
1/30/2004Meridian Bioscience Reports Completion of Exchange Offer
CINCINNATI--(BUSINESS WIRE)--Jan. 30, 2004--Meridian Bioscience, Inc., (NASDAQ:VIVO) today announced that its offer to exchange 5% Convertible Subordinated Debentures due 2013 for its outstanding 7% Convertible Subordinated Debentures due 2006, expired at 12:00 midnight EST on Wednesday, January 28, 2004. LaSalle Bank National Association, the exchange agent for the offer, has advised the Company that approximately $4 million in principal amount of the outstanding debentures was ten... 
 Printer Friendly Version
1/27/2004Meridian Bioscience Awarded New Rubella Patent
CINCINNATI, Jan 27, 2004 (BUSINESS WIRE) -- Meridian Bioscience, Inc., Cincinnati, Ohio (Nasdaq:VIVO) today announced that Viral Antigens, Inc. (VAI), a wholly owned life science subsidiary, received a patent entitled "Improved Specificity in the Detection of Anti-Rubella IgM Antibodies" from the U.S. Patent and Trademark Office. This patent encompasses improved methods for detection of anti-rubella IgM antibodies in commercial diagnostic products, utilized to test blood samples for the p... 
 Printer Friendly Version
1/22/2004Meridian Bioscience Reports Record Sales and Record First Quarter Operating Income, Declares First Quarter Higher Regular Cash Dividend, and Reaffirms Fiscal 2004 Guidance
CINCINNATI--(BUSINESS WIRE)--Jan. 22, 2004--Meridian Bioscience, Inc., (Nasdaq:VIVO) today: reported record quarterly net sales of $18,166,000, a 13% increase over the same period of the prior fiscal year and an all time record for any quarter in the Company's history; reported diluted net earnings of $1,795,000 or $0.12 per diluted share, a 26% increase over the same period of the prior fiscal year; reported record first quarter oper... 
 Printer Friendly Version
1/13/2004Meridian Bioscience to Begin Redeeming 7% Convertible Subordinated Debentures
CINCINNATI--(BUSINESS WIRE)--Jan. 13, 2004--Meridian Bioscience, Inc. (Nasdaq:VIVO) today announced that it will begin a program to redeem at par its outstanding issue of 7% Convertible Subordinated Debentures due 2006. The first call for redemption, in the amount of $4 million, will take place soon after January 28, 2004, the date when debentureholders lose their right to exchange their current debentures for new debentures. It is anticipated that the Company will make additional redempt... 
 Printer Friendly Version
1/12/2004Meridian Bioscience Hires Vice President of Sales and Marketing
CINCINNATI--(BUSINESS WIRE)--Jan. 12, 2004--Meridian Bioscience, Inc., (Nasdaq:VIVO) today announced that Gregory S. Ballish has joined Meridian Bioscience, Inc. as Vice President Sales and Marketing. Ballish joins Meridian as a pharmaceutical and diagnostics industry veteran, having spent the last five years in senior sales management and strategic customer marketing roles with Janssen Pharmaceutica (Johnson & Johnson subsidiary). Mr. Ballish has also held positions of national sales and... 
 Printer Friendly Version